Aesthetic Treatments for Middle Eastern and Darker Skin Types in the UAE

Published 1 April 2026 · Updated 19 August 2026

If your skin sits at Fitzpatrick III, IV or V, which covers most people of Middle Eastern descent, the question you are asking a clinic in the UAE is not really whether a treatment works. It is whether it will leave a brown mark behind. That risk has a name, post-inflammatory hyperpigmentation, and it changes the arithmetic of nearly every aesthetic decision you make. This page sets out what the published evidence supports for darker skin phototypes, where that evidence is thin, which of these treatments this clinic actually performs, and the questions worth asking before anyone switches a device on.

One caveat belongs at the top rather than buried at the bottom. Most of the research described here was carried out in Black and East Asian populations. Middle Eastern skin is barely represented in it. That gap is discussed in full further down, and it is the honest reason to treat everything below as a starting point for a consultation rather than a protocol.

What Fitzpatrick phototype actually describes, and what it does not

The Fitzpatrick scale sorts skin by how it responds to ultraviolet light, not by ethnicity or by the colour you see in a mirror. DermNet describes it as a constitutional characteristic present at birth, determined by the amount of melanin in the skin and by how that skin reacts to sun exposure. Pale skin burns easily and tans slowly. Darker skin burns less and tans more readily, and DermNet notes it is also more prone to develop post-inflammatory pigmentation after injury.

That last clause is the whole subject of this page. More melanin means more protection against burning and more raw material for a pigment response when the skin is injured, inflamed or heated. Both things are true at once.

The scale has real limits. It was built to predict sunburn, not to predict how skin responds to a radiofrequency handpiece or a glycolic acid solution. Two people can both be phototype IV and respond differently, because tanning history, hormones, medication and the specific condition being treated all feed into the pigment response. A phototype is a starting assumption for parameter selection. It is not a diagnosis, and no competent clinician should treat it as one.

Why post-inflammatory hyperpigmentation sits at the centre of every decision

Post-inflammatory hyperpigmentation is the flat brown or grey patch that appears after skin has been inflamed or injured. DermNet describes the mechanism plainly: inflammation in the epidermis stimulates melanocytes to increase melanin synthesis and transfer that pigment to the surrounding skin cells, which produces epidermal melanosis. If the basal layer of the skin is injured, melanin is released and then trapped by macrophages in the papillary dermis, which produces dermal melanosis, also called pigment incontinence.

The distinction matters commercially, because it predicts how long you will be living with the mark. Epidermal pigment sits shallow and fades over months. Dermal pigment sits deeper and can persist for years, and topical lightening agents reach it poorly.

DermNet states that post-inflammatory hyperpigmentation can occur in anyone but is more common in darker-skinned individuals, in whom the colour tends to be more intense and to persist for a longer period than in lighter skin. That single sentence explains why a treatment plan that is routine at phototype II becomes a conversation about risk at phototype V.

What the pigmentation review found across 1,356 patients

The most useful single document on this subject is a 2024 systematic review of treatments for post-inflammatory hyperpigmentation in skin of colour, indexed at PubMed under PMID 39075672. It pooled 48 studies covering 1,356 people. Mean age was 29. Seventy-eight per cent were women.

The phototype distribution was III in 20 per cent, IV in 40 per cent, V in 34 per cent and VI in 6 per cent. In 89 per cent of cases the pigmentation followed an inflammatory skin condition rather than a cosmetic procedure, and in 83 per cent it was on the face. The two most frequently studied treatments were topical retinoids, at 22 per cent of cases, and laser, at 17 per cent.

Now the results, which are more sobering than any clinic marketing suggests. Partial improvement was reported in 85 per cent of the retinoid cases and 66 per cent of the laser cases. Laser was the only modality that produced complete resolution in a subgroup, about 26 per cent, and it was also the modality with documented cases of pigmentation getting worse. Chemical peels accounted for 9 per cent of cases and hydroquinone 7 per cent, both less effective than the two leading options. The authors’ own summary of the field is worth quoting exactly: Our results show a lack of robust efficacy across all treatment modalities.

Read that sentence twice before you buy a package. The treatment with the highest ceiling is also the one that can make the problem worse, and no option in the published literature reliably clears post-inflammatory hyperpigmentation in darker skin.

The physics that decides whether a device is a reasonable bet

Energy-based devices differ in what they aim at. That single design choice drives most of the risk difference for darker skin, and it is the most useful thing a patient can understand before a consultation.

A 2023 review of energy-based devices in Fitzpatrick types IV to VI, PMID 37557909, lays out the distinction. Non-ablative fractional lasers target water in the tissue rather than melanin, which is why they carry a better safety margin in darker skin than devices built around a pigment target. A short-pulsed 1064 nm Nd:YAG laser, by contrast, targets melanin, haemoglobin and water together. Radiofrequency skin tightening works by heating tissue without the excessive surface heating that drives pigment reactions, and microfocused ultrasound produces thermal coagulation in deeper layers. The same review states that radiofrequency microneedling is a safe option for laxity and texture in these phototypes.

The practical translation is short. If a device’s working principle is to find pigment and destroy it, your own melanin is a competing target. If the device works through water or through controlled deep heating, your melanin is less in the firing line. That is a difference in category, not a difference in marketing.

Radiofrequency microneedling, and why it keeps surfacing first for darker skin

Radiofrequency microneedling delivers energy below the surface through fine needles, which spares the epidermis where most of the melanin sits. A 2021 review of the modality, PMID 33577211, assessed 42 studies of adequate quality: 14 on rejuvenation, 7 on post-acne scarring, 6 on acne, 5 on striae, 5 on hyperhidrosis and 2 on melasma. Its conclusion on safety states that the technique can be used repeatedly and safely in individuals with darker skin phototypes. The same review notes that tissue remodelling continues to improve for at least six months after a course, which is a reason to judge results late rather than early.

Mechanical microneedling without radiofrequency has a similar profile. A 2021 review of microneedling for scars, PMID 33376377, covering 58 studies and 1,845 patients, reported that no serious adverse events occurred across that body of work. The authors also point out that the technique has been used in Asia and the Middle East for decades, partly because of its presumed lack of pigmentary change even in darker phototypes, and they call for standardised protocols that do not yet exist.

Presumed is the operative word. A good safety record accumulated across small studies is genuinely reassuring, and it is not the same thing as a large randomised trial in phototype V and VI skin. That trial has not been done.

Where the fractional laser evidence is graded strong, and where it is not

An evidence-based review of non-ablative fractional lasers in Fitzpatrick types IV to VI, PMID 28979657, graded the literature by indication. Level 1 evidence supports use for acne, striae and skin rejuvenation. Level 2 evidence supports use for post-acne scarring, melasma, and surgical or traumatic scars.

The same review ends with a limitation that deserves as much weight as the grades: there is a paucity of high-quality studies involving skin types V and VI. Most of the reassurance in that literature is drawn from phototype IV. If your skin is at the darker end, you are extrapolating, and the clinician recommending the treatment should say so out loud.

Two further reviews sharpen the caution. A 2024 review of rosacea in skin of colour, PMID 39171934, which also reports prevalence of up to 10 per cent in these populations, notes that not all lasers and energy-based devices are safe in types IV to VI, because pigment absorbs more of the delivered energy and raises the risk of post-inflammatory hyperpigmentation and scarring. An older review of laser treatment in darker skin, PMID 14717412, is blunter still, and its recommendations have not been superseded: test spots first, conservative settings, and an operator with genuine experience in these phototypes.

Chemical peels, and the line between superficial and everything else

DermNet is direct on this point. Chemical peels are most often used in patients with fair skin, Fitzpatrick types I to III, and its contraindications section states that patients with Fitzpatrick skin types IV to VI have increased risk of dyspigmentation, hypertrophic and keloid scarring, so peels must be performed cautiously with full patient informed consent. A 2013 review in the British Journal of Dermatology, PMID 24098904, puts the same risk in harder language: the higher risk of post-inflammatory dyschromias and abnormal scarring makes peels potentially disfiguring in ethnic skin.

The current picture is not uniformly discouraging. A 2026 scoping review of chemical peels in skin of colour, PMID 42306365, screened 473 studies and found only 7 that met inclusion criteria. Five of those, all in acne and post-acne pigmentation, reported positive outcomes with minimal adverse events. One covered lichen planus pigmentosus. One described chemical burns caused by improper application. Superficial glycolic and salicylic acid peels showed promising results, and the authors flag the same limitations that run through this entire field: small samples, short follow-up, and under-representation of types IV to VI.

Seven usable studies out of 473 is the real headline. It is enough to justify a superficial peel performed carefully by someone who knows these phototypes. It is not enough to justify a medium-depth peel sold as a routine facial. DermNet advises waiting three to six months before repeating a moderate-depth peel, and that interval exists for a reason.

Med Yu Med performs chemical peels in the superficial range, and the longer explainer on how the depths differ sits in the guide to peel types and results.

Keloid risk is a separate problem from pigment

Pigment fades, slowly and sometimes incompletely. A keloid does not. It is a distinct risk with a distinct anatomy, and it is easy to overlook in a conversation that has been focused entirely on brown marks.

DermNet describes keloids as scars that extend beyond the original wound margin, in contrast to hypertrophic scars, which stay within the area of damaged skin. Keloids can arise months to years after an injury, and they can follow trauma as minor as an insect bite, a burn, cryotherapy, acne, an infection or a vaccination. The upper chest, shoulders, ears and neck are described as especially prone.

For anyone considering an ablative or aggressive resurfacing treatment, a personal or family history of keloid scarring changes the calculation completely, and it belongs in the consultation before any device is selected.

Melasma is not post-inflammatory hyperpigmentation, and the difference is expensive

These two conditions get treated as one thing in clinic marketing. They behave differently.

DermNet’s treatment section for melasma opens with general measures rather than procedures: year-round, life-long sun protection, a broad-brimmed hat, SPF50+ sunscreen containing iron oxides, sun-smart behaviour, and discontinuing hormonal contraception where possible. On topical therapy, it reports that the most successful formulation has been a combination of hydroquinone, tretinoin and a moderate-potency topical steroid, reported to clear or improve 60 to 80 per cent of cases. Oral tranexamic acid is described as a further option. DermNet also emphasises that the chronicity and risk of relapse, with the need for lifelong sun protection, should be discussed to set realistic goals.

Relapse is the point. Melasma is a recurring condition managed over years, not a mark cleared once. Anyone offering to remove it permanently with a course of treatments is describing something the literature does not support. Prescription-only agents such as hydroquinone and tretinoin are named here because DermNet names them, and they require a physician’s assessment and prescription. This page is not a recommendation to obtain or use them.

Separate reading on why pigmentation returns is available in the explainer on recurrent pigmentation, and the clinic’s own service page for these concerns is pigmentation treatment in Dubai.

What this clinic performs

Some of the evidence above concerns treatments that sit outside the scope of this page, and saying which is which is more useful than blurring them together.

The clinic works on two tracks. Alongside the devices and topical treatments named above, it performs botulinum therapy, hyaluronic acid lip filler, mesotherapy, biorevitalization with hyaluronic acid, amino acids and PDRN, collagen stimulator therapy, and PRP prepared from the patient’s own blood. The treatments discussed on this page are the device-based and topical ones, because those are where phototype changes the decision most sharply.

What is available falls into a few groups. Radiofrequency microneedling is offered as Morpheus8, Genius by Lutronic and Vivace. Monopolar radiofrequency is offered as VOLNEWMER. Microfocused ultrasound for lifting is offered as Ultraformer MPT. Laser work is performed on the Fotona platform. The remaining options are lower-intensity: INDIBA, Endospheres, HELEO Pro LED, Endolift, plus peels and facial cleansing.

Naming a device is not the same as promising it suits your skin. Settings, depth, passes and intervals are chosen per patient, and for phototypes IV to VI the sensible default across all of the reviews cited above is conservative parameters and fewer of them.

Test spots, and why skipping them is a red flag

A test spot is a small area treated at the intended settings, then left alone long enough for a delayed pigment reaction to appear. The recommendation is old and has not been withdrawn. PMID 14717412 lists test spots, conservative settings and operator experience as the core precautions for laser treatment in darker skin, and the more recent reviews repeat the principle rather than replacing it.

The waiting period is the part people want to skip. Post-inflammatory hyperpigmentation does not appear the same day. If a clinic offers a test spot and then books your full treatment for the following morning, the test has told nobody anything.

A reasonable interval is two to four weeks between the test and the full treatment for a device with meaningful pigment risk. If a clinic declines to do a test spot at all on phototype IV or above, that is worth treating as information about the clinic.

Sun exposure in the UAE, and why aftercare decides the result

Ultraviolet exposure in this region is high year-round, and every source cited here converges on the same aftercare instruction. DermNet’s treatment section for post-inflammatory hyperpigmentation states that if pigmentation affects an exposed site, daily application of SPF 50+ broad-spectrum sunscreen is important to minimise darkening caused by ultraviolet radiation. Its melasma guidance goes further and specifies sunscreen containing iron oxides, which also blocks visible light.

This is not a soft recommendation appended to the end of a treatment plan. Skipping sun protection after a procedure that has deliberately inflamed the skin is the most reliable way to produce the exact mark the treatment was meant to remove.

What a first consultation should cover before any device touches your skin

A consultation that ends with a package price and no risk conversation has not been a consultation.

Expect the clinician to cover the following.

• Your phototype and your tanning history, including recent sun exposure.
• The diagnosis itself, confirmed rather than accepted from your description.
• Whether melasma is involved, and whether it has recurred before.
• Personal or family history of keloid scarring.
• Current medications, including anything photosensitising and any hormonal contraception.
• Whether the existing marks look epidermal or dermal, since that predicts how they respond.
• What happens if pigmentation appears after treatment.

That last item is the one most often missing. Ask directly what the plan is if the treatment causes a mark, who pays for managing it, and how long they expect it to take to resolve.

Questions worth asking before you agree to a course

Five questions separate a treatment plan from a sales script.

How many patients at my phototype has this specific operator treated on this specific device? What settings will be used, and how do they differ from the settings used on lighter skin? Will there be a test spot, and how long will you wait before the full treatment? What is the expected result at three months rather than immediately after, since remodelling continues for months? And what is the published evidence for this treatment in my phototype specifically, not in skin of colour as a broad category?

Answers of the form we do this all the time are not answers to any of those five.

Risks, and who should postpone

Every treatment described on this page carries risk, and the risks are higher in darker skin than the same procedure carries in lighter skin.

These are the risks documented across the literature cited above.

• Post-inflammatory hyperpigmentation, the most common of them.
• Hypopigmentation, which DermNet describes as usually permanent after more severe injury.
• Hypertrophic and keloid scarring, particularly with peels and ablative treatments in types IV to VI.
• Chemical burns from improperly applied peels, documented in one of the seven studies included in the 2026 scoping review.
• Worsening of existing pigmentation, documented specifically with laser in the 2024 systematic review.
• Prolonged redness, swelling and discomfort after microneedling and radiofrequency treatments.

Postpone or reconsider in the following situations.

• Pregnancy or breastfeeding.
• An active infection or inflammatory flare in the treatment area.
• Recent use of oral isotretinoin.
• A personal or family history of keloid scarring, where an ablative treatment is proposed.
• Tanned skin at the time of the appointment.
• Current use of a photosensitising medication.

Each of these is a conversation with the treating physician rather than a rule to apply yourself.

What the evidence does not settle

Three gaps deserve stating plainly, because no clinic page benefits from them being visible.

First, Middle Eastern skin is barely studied. The 2024 systematic review that anchors this page reported its population as 70 per cent Black, 27 per cent Asian and 3 per cent Latin. Arab and Persian populations are effectively absent from that dataset, so applying its findings to a patient in Dubai is an extrapolation across ethnicity as well as across phototype. That is a real limitation and no amount of confident phrasing removes it.

Second, types V and VI are under-represented even within the skin of colour literature. The fractional laser review says so directly. The peel scoping review says so. The consequence is that the darker your skin, the thinner the evidence supporting whatever you are being offered.

Third, protocols are not standardised. The microneedling scar review calls for standardised protocols that do not exist yet. Needle depth, energy, passes and intervals vary between studies, which means a published safety record attaches to the parameters used in that study rather than to the device sitting in any given clinic.

None of this means these treatments do not work. It means the honest description of the current state is that several are reasonably supported at phototypes III and IV, less well supported at V, and largely unstudied at VI.

When this needs a doctor now

Some post-treatment findings are not part of normal healing.

Seek medical attention the same day for any of these.

• Spreading redness with heat and pain, which can indicate infection.
• Blistering or an open wound in the treated area.
• Pigment loss producing a white patch rather than a brown one.
• A raised scar that keeps growing weeks after treatment.
• Fever following a procedure.

In a medical emergency in the UAE, call 998.

Medically reviewed by

DR. Ilias Ildarovich Dautov

General Practitioner, Aesthetic Medicine Doctor, Dermatologist

DHA License No. 09620692-002